VBI Vaccines (NASDAQ: VBIV) and Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares VBI Vaccines and Tetralogic Pharmaceuticals Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines N/A N/A N/A
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%

Institutional and Insider Ownership

31.5% of VBI Vaccines shares are held by institutional investors. Comparatively, 2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. 34.1% of VBI Vaccines shares are held by company insiders. Comparatively, 24.0% of Tetralogic Pharmaceuticals Corp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares VBI Vaccines and Tetralogic Pharmaceuticals Corp’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VBI Vaccines $888,999.00 172.86 -$32.88 million N/A N/A
Tetralogic Pharmaceuticals Corp N/A N/A -$21.14 million ($1.76) -0.03

Tetralogic Pharmaceuticals Corp has higher revenue, but lower earnings than VBI Vaccines.

Analyst Ratings

This is a summary of recent ratings and price targets for VBI Vaccines and Tetralogic Pharmaceuticals Corp, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 2 0 3.00
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A

VBI Vaccines currently has a consensus price target of $6.00, indicating a potential upside of 57.07%. Given VBI Vaccines’ higher probable upside, equities research analysts plainly believe VBI Vaccines is more favorable than Tetralogic Pharmaceuticals Corp.

Risk and Volatility

VBI Vaccines has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Summary

VBI Vaccines beats Tetralogic Pharmaceuticals Corp on 6 of the 8 factors compared between the two stocks.

VBI Vaccines Company Profile

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Tetralogic Pharmaceuticals Corp Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Stock Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related stocks with our FREE daily email newsletter.